Prostaglandins: Chemical and Biochemical Aspects

Free download. Book file PDF easily for everyone and every device. You can download and read online Prostaglandins: Chemical and Biochemical Aspects file PDF Book only if you are registered here. And also you can download or read online all Book PDF file that related with Prostaglandins: Chemical and Biochemical Aspects book. Happy reading Prostaglandins: Chemical and Biochemical Aspects Bookeveryone. Download file Free Book PDF Prostaglandins: Chemical and Biochemical Aspects at Complete PDF Library. This Book have some digital formats such us :paperbook, ebook, kindle, epub, fb2 and another formats. Here is The CompletePDF Book Library. It's free to register here to get Book file PDF Prostaglandins: Chemical and Biochemical Aspects Pocket Guide.

DOI: Lars Orning and F. Biochemistry , 31 17 , Armando, Edward A. Quantitative determination of esterified eicosanoids and related oxygenated metabolites after base hydrolysis. Journal of Lipid Research , 59 12 , Antioxidants , 7 11 , Eicosanomic profiling reveals dominance of the epoxygenase pathway in human amniotic fluid at term in spontaneous labor. Ulrich Kragh-Hansen. Molecular and practical aspects of the enzymatic properties of human serum albumin and of albumin—ligand complexes.

Atherosclerosis: A redox-sensitive lipid imbalance suppressible by cyclopentenone prostaglandins. Biochemical Pharmacology , 75 12 , Azim, John W. Christman, Richard B. Analytical Biochemistry , 1 , Prostaglandin D2 induces programmed cell death in Trypanosoma brucei bloodstream form. Influence of albumin. Journal of Hepatology , 42 1 , Philip J. Journal of Biological Chemistry , 2 , Kevin R.

Kozak, Brenda C. Crews, Jennifer L. Morrow, Lawrence J.

Journal of Biological Chemistry , 40 , Inflammation, carcinogenesis and cancer. International Immunopharmacology , 1 , Karen Still, Andrew Scutt. Stimulation of CFU-f formation by prostaglandin E2 is mediated in part by its degradation product, prostaglandin A2. Eric C. Person, Leslie L.

Waite, Robert N. Taylor, Thomas S. Endocrinology , 2 , Moos, K. Edes, F. Inactivation of wild-type p53 tumor suppressor by electrophilic prostaglandins.

Proceedings of the National Academy of Sciences , 97 16 , Opas, Gideon A. Gregory Seedor, Peter C.

Prostaglandins: chemical and biochemical aspects - Sultan M. M. Karim - Google книги

Tyler, Robert N. Prostaglandin E2-bisphosphonate conjugates: potential agents for treatment of osteoporosis. WANG, J. Prostaglandin D2 measurement in nasal secretions is not a reliable marker for mast cell activation in atopic patients. Prostaglandins , 49 4 , Judy Parker, Patricia B. Ahrens, Helmut Ankel. Antiviral effect of cyclopentenone prostaglandins on vesicular stomatitis virus replication. Antiviral Research , 26 1 , Journal of Pharmacy and Pharmacology , 46 10 , Judy Parker, Helmut Ankel.

Formation of a prostaglandin A2-glutathione conjugate in L mouse leukemia cells. Biochemical Pharmacology , 43 5 , Hormone binding to natural mutants of human serum albumin. European Journal of Biochemistry , 1 , Nushin K. Farzaneh, Thomas L. Walden, Vincent J. Prostaglandins--physiological, pharmacological and pathological aspects Book 9 editions published in in English and held by WorldCat member libraries worldwide.

Account Options

Practical applications of prostaglandins and their synthesis inhibitors by Sultan M. From laboratory and animal studies a large number of practical applications of prostaglandins have been identified. In some areas clinical trials have also been carried out. There is usually a long time interval between identifying practical applications of new drugs and clinical trials. Most of the information on practical applications of prostaglandins is scattered in different journals. Although a number of books dealing with prostaglandin research have been published including some on practical applications in specific areas, e.

This book aims at filling this gap and should be of interest to clinicians as well as to medical and basic scientists in academic institutions and in the pharmaceutical industry. In some areas, exciting potential applications of prostaglandins have been identified from basic research but clinical trials have so far not been carried out. Such areas of practical applications are covered in a separate intro ductory chapter. All contributors to the volume are scientists and clinicians actively engaged in prostaglandin research and most are recognized authorities in specific areas.

The need for rapid publication in a fast-expanding field is obvious. Obstetric and gynaecological uses of prostaglandins : congress proceedings by Asian Federation of Obstetrics and Gynaecology Book 9 editions published in in English and held by WorldCat member libraries worldwide.

  • Karim, Sultan M. M.;
  • Prostaglandin H Synthase?
  • Prostaglandins & Other Lipid Mediators?
  • Product details.
  • Prostaglandins: Chemicals and Biochemical Aspects;

Cervagem : a new prostaglandin in obstetrics and gynaecology : proceedings of a symposium held at the Shangri-La Hotel, Singapore, 31 July by Sultan M. I hope that it is not necessary for me to intro duce myself, as Singapore doctors have received my letter of invitation and overseas delegates have received my letter of welcome. It is my very pleasant duty to introduce our Director of Research, Dr J.

Biochemical Aspects of Prostaglandins and Thromboxanes

McFadzean, who has come specially to grace this occasion. Dr McFadzean, Sir, may I invite you to say a few words to this gathering of distinguished participants. It is appropriate that this Symposium on Cervagem be held in South-east Asia where so much excellent development work was done with this product.

It has been a most happy collaboration from the time the active ingredient ONO was synthesized by the Ono Company. Fullerton, Calif. These systems typically automate entire procedures including all sample and reagent pipetting, liquid dispensing, timed incubations, and final reading of the samples in detector s appropriate for the assay. These configurable systems provide high throughput and rapid start up as well as a high degree of flexibility and customization. The manufacturers of such systems provide detailed protocols for the various high throughput assays.

The present invention is not limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and the accompanying figures.

Such modifications are intended to fall within the scope of the appended claims. The plates are incubated overnight at 37 0 C. The compound plate s and reference control are thawed and mixed well before use. Test compound and reference SC dilutions are made with a Costar or equivalent assay block according to the EIA template shown below. Controls 1, 2, 5 and 6 are positive controls containing calcium ionophore without compound.

Controls 3, 4, 7 and 8 are negative controls without calcium ionophore or compound. Add 3 ul of compound stock [10 mM] to 30 uM wells. Mix well. Add ul from row A [30 uM] to row B [10 uM]. Continue diluting as above, to generate the following concentrations [30, 10, 3. Add ul of HBSS with 0. Continue diluting to generate the following concentrations [3 uM, 1 uM, 0. An automated cell treatment for the addition of calcium ionophore A Sigma C and methoximating reagent prepared according to Cayman kit directions was designed using a Zymark SciClone Deck.


The present automated A protocol requires that a number of steps be performed manually M as outlined below. M Cover and return cell plates to 37 0 C.

No customer reviews

Incubate for 15 minutes. Uncover cell plates and return to deck. A Add 10 ul of 2Ox concentration to ul cell treatments including positive control wells. Note there is no addition of calcium ionophore to negative control wells. M Remove empty tip boxes and replace with ul tips at deck locations B2, B3, and B4. M Centrifuge plates x rpm for 5 minutes. See following example.

A Collect ul of remaining supernatant to be evaluated for PGE2. After washing the plate, Ellman's Reagent which contains the substrate to AchE is added to the well. The enzymatic product has a distinct yellow color, which absorbs strongly at nm. The intensity of this color is proportional to the amount of. The EIA and wash buffers were made according to the commercial instructions. Samples were prepared according to the previous example. Since prostaglandin levels may vary, the supernatants are diluted with EIA buffer to yield prostaglandin levels within the linear range of the standard curve.

Commonly used PGD2 dilutions are 1 : The assay was performed according to the manufacturer's instructions and the plates were read at a wavelength of nm. After the prostaglandin levels were determined in cells treated with 8 concentrations of test compounds, an IC50 of the compound may be generated by conducting a semi-log plot of the prostaglandin level versus log scale of the compound concentration. This assay can also be conducted as a single point assay evaluating the inhibition of compound on PGD2 production using only one concentration of compound.

The anti-PGE2 antibody is then fixed using a goat anti-mouse Ig antibody. The fixed antibody is then developed with Ellman's Reagent, which contains the substrate for acetylcholinesterase. The product produced by this reaction has a yellow color, and absorbs strongly at nm. If there is a high concentration of PGE2, the PGE2 will outcompete the tracer and the resulting sample will have a weak absorbance at nm. Conversely, if there is a low concentration of PGE2, the tracer will outcompete the PGE2 and the resulting sample will have a strong absorbance at nm.

In performing this assay, the absorbance at nm was compared to a standard of absorbances at known concentrations of PGE2. This assay may be easily converted to automated format by one skilled in the art by using a Zymark SciClone Deck, for example. This example shows how the above PGD2 and PGE2 cell-based assays may be used to distinguish between specific and non-specific compounds. As shown in Figure 1, compound A generates an IC50 value of 2. A subsequent cytotoxicity study confirmed that compound AOOO affects cell proliferation under the testing conditions. In this example, RBL cells were treated with the PGDS compounds for 45 min under the same condition as in the cell-based assay except no A was added.

The assay was carried out following the manufacturer's instruction. Eight concentrations of each compound ranging from 0. The testing concentrations were 0. Compound A and another PGDS compound, A, were toxic, which are distinguishable from a number of non-toxic test compounds shown in the same plot. Geneticin was used as a positive control. Kind code of ref document : A1. Ref document number : Country of ref document : US. Country of ref document : MX.

Country of ref document : IL. Country of ref document : CA. Country of ref document : AU. Country of ref document : JP. Country of ref document : KR. Country of ref document : CN. Ref country code : DE. Country of ref document : IN. Date of ref document :

go to site admin